Your browser doesn't support javascript.
loading
Posterior reversible encephalopathy syndrome (PRES) and myeloma.
Ghanem, Ricardos; Glaisner, Sylvie; Bobin, Arthur; Ronchetti, Anne-Marie; Cereja, Sophie; Joly, Bertrand; Salanoubat, Célia; Fouquet, Guillemette.
Afiliação
  • Ghanem R; Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.
  • Glaisner S; Département d'oncologie médicale, Institut Curie, Paris, France.
  • Bobin A; Service d'Hématologie et Thérapie Cellulaire, Pôle Régional de Cancérologie, CHU de Poitiers, France.
  • Ronchetti AM; Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.
  • Cereja S; Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.
  • Joly B; Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.
  • Salanoubat C; Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.
  • Fouquet G; Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.
Leuk Res Rep ; 21: 100407, 2024.
Article em En | MEDLINE | ID: mdl-38260821
ABSTRACT
Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Leuk Res Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Leuk Res Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França